- Alterity Therapeutics (ATH) says it has secured a “broad monopoly” over a class of compounds capable of redistributing excess iron in the central nervous system
- The patent covers small molecule drug candidates which could be used to target excess iron in patients with Alzheimer’s and Parkinson’s disease
- It comes as the company gears up for phase two of its lead clinical candidate ATH434, due to take place by the end of the year
- The patent was issued by the United States Patent and Trademark Office and is granted to Alterity for 20 years
- Alterity Therapeutics closed today’s session up 7.14 per cent at 3 cents
Alterity Therapeutics (ATH) says it has secured a “broad monopoly” over a class of compounds capable of redistributing excess iron in the central nervous system.
Specifically, the patent covers small molecule drug candidates, which ATH claim has potential to cross the blood-brain barrier and directly attack a source of
neuropathology.
Excess iron in the brain is associated with neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.
Following the grant of “Compounds for and Methods of Treating Diseases”, ATH now has rights to more than 150 novel pharmaceutical compositions aimed at redistributing iron in patients with said diseases.
The patent grant comes as the company gears up for the phase two trial of its lead clinical candidate ATH434 — to treat Multiple System Atrophy — due to take place by the end of the year.
Alterity Chief Executive officer Dr David Stamle said the patent represented an important part of its corporate strategy.
“The newly covered compounds target excess brain iron that is increased in these
conditions and we hope to identify a new clinical candidate by the time we get results from our lead clinical program,” he said.
The patent was issued by the United States Patent and Trademark Office and is granted to Alterity for 20 years.
Alterity Therapeutics closed today’s session up 7.14 per cent at 3 cents.